Nurix Therapeutics, Inc. 8-K

What Happened On April 8, 2026, Nurix Therapeutics, Inc. announced its financial results for the fiscal quarter ended February 28, 2026 via a press release. The company furnished that press release as Exhibit 99.1 to its Form 8-K. The Form 8-K was signed by Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer.

Key Details

• Filing date: April 8, 2026 (Form 8-K, Item 2.02 – Results of Operations and Financial Condition).
• Quarter covered: fiscal quarter ended February 28, 2026.
• Press release: furnished as Exhibit 99.1 to the 8-K (also included interactive XBRL cover page file).
• Signature: Form 8-K signed by CEO Arthur T. Sands, M.D., Ph.D.

Why It Matters This 8-K notifies investors that Nurix has released its latest quarterly earnings and related financial information; investors should review the attached press release (Exhibit 99.1) for specifics on revenue, expenses, net income or loss, cash position and any commentary on business progress or guidance. Because the 8-K furnishes the press release rather than embedding full financial statements in the filing text, the exhibit is the primary source for the quarter’s numeric results and management commentary.